Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2012, Article ID 703281, 4 pages
http://dx.doi.org/10.1155/2012/703281
Case Report

Complete Remission of Human Parvovirus B19 Associated Symptoms by Loxoprofen in Patients with Atopic Predispositions

1Department of Physiology I, Tohoku University Graduate School of Medicine, Seiryo-cho, Aoba-ku, Sendai, Miyagi 980-8575, Japan
2Department of Internal Medicine, Iwakiri Hospital, Miyagino-ku, Sendai, Miyagi 983-0821, Japan

Received 10 February 2012; Revised 14 March 2012; Accepted 16 March 2012

Academic Editor: Dierk Thomas

Copyright © 2012 Itsuro Kazama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Woolf, G. V. Campion, A. Chishick et al., “Clinical manifestations of human parvovirus B19 in adults,” Archives of Internal Medicine, vol. 149, no. 5, pp. 1153–1156, 1989. View at Google Scholar · View at Scopus
  2. A. Lindblom, A. Isa, O. Norbeck et al., “Slow clearance of human parvovirus B19 viremia following acute infection,” Clinical Infectious Diseases, vol. 41, no. 8, pp. 1201–1203, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. T. H. Finkel, T. J. Torok, P. J. Ferguson et al., “Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?” The Lancet, vol. 343, no. 8908, pp. 1255–1258, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. E. D. Heegaard, H. Eiskjær, U. Baandrup, and A. Hornsleth, “Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation,” Scandinavian Journal of Infectious Diseases, vol. 30, no. 6, pp. 607–610, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Douvoyiannis, N. Litman, and D. L. Goldman, “Neurologic manifestations associated with parvovirus B19 infection,” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1713–1723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Meyer, “Parvovirus B19 and autoimmune diseases,” Joint Bone Spine, vol. 70, no. 1, pp. 6–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. T. F. Schwarz, S. Wiersbitzky, and M. Pambor, “Case report: detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum,” Journal of Medical Virology, vol. 43, no. 2, pp. 171–174, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Nikkari, A. Roivainen, P. Hannonen, T. Mottonen, R. Luukkainen, and T. Yli-Jama, “Persistence of parvovirus B19 in synovial fluid and bone marrow,” Annals of the Rheumatic Diseases, vol. 54, no. 7, pp. 597–600, 1995. View at Google Scholar · View at Scopus
  9. S. J. Naides, L. L. Scharosch, F. Foto, and E. J. Howard, “Rheumatologic manifestations of human parvovirus B19 infection in adults: Initial two-year clinical experience,” Arthritis and Rheumatism, vol. 33, no. 9, pp. 1297–1309, 1990. View at Google Scholar · View at Scopus
  10. N. S. Young and K. E. Brown, “Parvovirus B19,” The New England Journal of Medicine, vol. 350, no. 6, pp. 586–597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. J. Anderson, P. G. Higgins, L. R. Davis et al., “Experimental parvoviral infection in humans,” Journal of Infectious Diseases, vol. 152, no. 2, pp. 257–265, 1985. View at Google Scholar · View at Scopus
  12. E. D. Heegaard and K. E. Brown, “Human parvovirus B19,” Clinical Microbiology Reviews, vol. 15, no. 3, pp. 485–505, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. M. H. Liang, P. Fortin, M. Schneider et al., “The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity,” Arthritis and Rheumatism, vol. 50, no. 11, pp. 3418–3426, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Nesher, T. G. Osborn, and T. L. Moore, “Parvovirus infection mimicking systemic lupus erythematosus,” Seminars in Arthritis and Rheumatism, vol. 24, no. 5, pp. 297–303, 1995. View at Google Scholar · View at Scopus
  15. V. Feizy and A. Ghobadi, “Atopic dermatitis and systemic autoimmune diseases: a descriptive cross-sectional study,” Dermatology Online Journal, vol. 12, no. 3, 2006. View at Google Scholar · View at Scopus
  16. K. Takeoka, Y. Hidaka, H. Hanada et al., “Increase in serum levels of autoantibodies after attack of seasonal allergic rhinitis in patients with graves' disease,” International Archives of Allergy and Immunology, vol. 132, no. 3, pp. 268–276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Astrakhan, M. Omori, T. Nguyen et al., “Local increase in thymic stromal lymphopoietin induces systemic alterations in B cell development,” Nature Immunology, vol. 8, no. 5, pp. 522–531, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Broliden, T. Tolfvenstam, and O. Norbeck, “Clinical aspects of parvovirus B19 infection,” Journal of Internal Medicine, vol. 260, no. 4, pp. 285–304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Yoshidome, S. Hayashi, T. Okadome, Y. Maruyama, and K. Nishitarumizu, “Eight cases of human parvovirus B19 arthropathy,” Nihon Naika Gakkai Zasshi, vol. 93, no. 2, pp. 377–379, 2004. View at Google Scholar · View at Scopus
  20. K. Ichinose, K. Migita, T. Sekita et al., “Parvovirus B19 infection and myofasciitis,” Clinical Rheumatology, vol. 23, no. 2, pp. 184–185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Y. Cho, “Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses,” Archives of Pharmacal Research, vol. 30, no. 1, pp. 64–74, 2007. View at Google Scholar · View at Scopus
  22. D. J. Wallace, “Advances in drug therapy for systemic lupus erythematosus,” BMC Medicine, vol. 8, article 77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. C. Gotzsche, “Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis,” Controlled Clinical Trials, vol. 10, no. 1, pp. 31–56, 1989. View at Google Scholar · View at Scopus
  24. M. A. Iniguez, C. Punzon, and M. Fresno, “Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors,” Journal of Immunology, vol. 163, no. 1, pp. 111–119, 1999. View at Google Scholar
  25. H. Hackstein, A. E. Morelli, A. T. Larregina et al., “Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells,” Journal of Immunology, vol. 166, no. 12, pp. 7053–7062, 2001. View at Google Scholar · View at Scopus
  26. J. X. Gao and A. C. Issekutz, “The effect of ebselen on polymorphonuclear leukocyte migration to joints in rats with adjuvant arthritis,” International Journal of Immunopharmacology, vol. 15, no. 7, pp. 793–802, 1993. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Kazama, Y. Maruyama, and Y. Murata, “Suppressive effects of nonsteroidal anti-inflammatory drugs diclofenac sodium, salicylate and indomethacin on delayed rectifier K+-channelcurrents in murine thymocytes,” Immunopharmacology and Immunotoxicology. In press. View at Publisher · View at Google Scholar
  28. R. S. Lewis and M. D. Cahalan, “Potassium and calcium channels in lymphocytes,” Annual Review of Immunology, vol. 13, pp. 623–653, 1995. View at Google Scholar · View at Scopus